TY - BOOK ID - 1720899 TI - Drug-like properties AU - Kerns, Edward Harvel AU - Di, Li PY - 2008 SN - 9780123695208 0123695201 9780080557618 0080557619 9786611763718 0080951627 1281763713 PB - Amsterdam Boston Academic Press DB - UniCat KW - Pharmacology. Therapy KW - Drug Design. KW - Drug Evaluation, Preclinical. KW - Drug Toxicity. KW - Pharmaceutical Preparations KW - Pharmacokinetics. KW - Structure-Activity Relationship. KW - Pharmaceutical chemistry. KW - Drugs KW - Drug development. KW - Chimie pharmaceutique KW - Médicaments KW - metabolism. KW - Structure-activity relationships. KW - Design. KW - Relations structure-activité KW - Développement KW - Conception KW - Pharmaceutical chemistry KW - Drug development KW - Structure-activity relationships KW - Design KW - Drug design KW - Pharmaceutical design KW - Development of drugs KW - New drug development KW - Pharmacology KW - Pharmacy KW - Structure-activity relationship (Pharmacology) KW - Structure-activity relationships (Biochemistry) KW - Chemistry, Medical and pharmaceutical KW - Chemistry, Pharmaceutical KW - Drug chemistry KW - Medical chemistry KW - Medicinal chemistry KW - Pharmacochemistry KW - Chemistry KW - Development KW - Drug-Related Side Effects and Adverse Reactions. KW - Drugs - Structure-activity relationships KW - Drugs - Design UR - https://www.unicat.be/uniCat?func=search&query=sysid:1720899 AB - Of the thousands of novel compounds that a drug discovery project team invents and that bind to the therapeutic target, typically only a fraction of these have sufficient ADME/Tox properties to become a drug product. Understanding ADME/Tox is critical for all drug researchers, owing to its increasing importance in advancing high quality candidates to clinical studies and the processes of drug discovery. If the properties are weak, the candidate will have a high risk of failure or be less desirable as a drug product. ER -